Automate Your Wheel Strategy on QURE
With Tiblio's Option Bot, you can configure your own wheel strategy including QURE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol QURE
- Rev/Share 0.2692
- Book/Share 3.9091
- PB 7.0374
- Debt/Equity 0.2892
- CurrentRatio 7.117
- ROIC -0.238
- MktCap 1489037814.0
- FreeCF/Share -2.6488
- PFCF -9.6069
- PE -6.8459
- Debt/Assets 0.0745
- DivYield 0
- ROE -3.7373
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | QURE | William Blair | Outperform | Market Perform | -- | -- | Nov. 4, 2025 |
| Upgrade | QURE | Mizuho | Neutral | Outperform | -- | $30 | Aug. 14, 2025 |
| Resumed | QURE | Chardan Capital Markets | -- | Buy | -- | $38 | April 1, 2025 |
| Upgrade | QURE | Raymond James | Outperform | Strong Buy | -- | -- | Dec. 10, 2024 |
| Resumed | QURE | Raymond James | -- | Outperform | -- | $20 | Oct. 10, 2024 |
News
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
Published: November 28, 2025 by: PRNewsWire
Sentiment: Neutral
RADNOR, Pa., Nov. 28, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDAQ: QURE) ("uniQure").
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of uniQure N.V. - QURE
Published: November 20, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE).
Read More
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
Published: November 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
RADNOR, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDAQ: QURE) (“uniQure”).
Read More
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm
Published: November 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 12, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of uniQure N.V. (“uniQure” or “the Company”) (NASDAQ: QURE) for violations of the securities laws.
Read More
From Setback To Surge: UniQure's Huntington's Hope Is Poised For Upside
Published: November 10, 2025 by: Seeking Alpha
Sentiment: Positive
UniQure stock is rated a Buy with a $66 price target, offering upside after recent FDA pushback on AMT-130 Huntington's therapy trial design. AMT-130 is the first disease-modifying therapy for Huntington's, showing 75% slowing of disease progression and significant functional benefit in Phase 1/2 data. Modeling suggests a 78% probability of eventual approval (accelerated or post-Phase 3), with near-term catalysts including FDA meeting minutes and EMA discussions.
Read More
uniQure N.V. (QURE) Q3 2025 Earnings Call Transcript
Published: November 10, 2025 by: Seeking Alpha
Sentiment: Neutral
uniQure N.V. ( QURE ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Chiara Russo - Senior Director of Investor Relations Matthew Kapusta - CEO & Executive Director Walid Abi-Saab - Chief Medical Officer Kylie O'Keefe - Chief Customer & Strategy Officer Christian Klemt - CFO, Principal Financial Officer & GM of Amsterdam Site Conference Call Participants Joseph Schwartz - Leerink Partners LLC, Research Division Uy Ear - Mizuho Securities USA LLC, Research Division Lydia Erdman - Goldman Sachs Group, Inc., Research Division Joseph Thome - TD Cowen, Research Division Luca Issi - RBC Capital Markets, …
Read More
uniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates
Published: November 10, 2025 by: Zacks Investment Research
Sentiment: Negative
uniQure (QURE) came out with a quarterly loss of $1.38 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to a loss of $0.91 per share a year ago.
Read More
UNIQURE ALERT: Bragar Eagel & Squire, P.C. is Investigating uniQure N.V.
Published: November 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
uniQure disclosed the FDA no longer agrees its AMT-130 trial data may support a BLA submission, making timing unclear. Shares fell over 57% on the news.
Read More
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm
Published: November 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of uniQure N.V. (“uniQure” or “the Company”) (NASDAQ: QURE) for violations of the securities laws.
Read More
NASDAQ: QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
Published: November 04, 2025 by: Business Wire
Sentiment: Neutral
RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDAQ: QURE) (“uniQure”). On November 3, 2025, uniQure issued a press release revealing that the FDA notified the company that data for its AMT-130, an investigational gene therapy for Huntington's disease, did not provide sufficient evidence to support uniQure's Biologics Licen.
Read More
QURE Investor ALERT: Block & Leviton Investigating uniQure for Securities Fraud; Investors Should Contact the Firm to Potentially Recover Losses
Published: November 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating UniQure N.V. (NASDAQ: QURE) for potential securities law violations.
Read More
INVESTOR ALERT: Investigation of uniQure N.V. (QURE) Announced by Holzer & Holzer, LLC
Published: November 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
INVESTOR ALERT: Investigation of uniQure N.V. (QURE) Announced by Holzer & Holzer, LLC ATLANTA, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether uniQure N.V.
Read More
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm
Published: November 03, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)---- $QURE--QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm.
Read More
Uniqure stock plunges after FDA rejects company's clinical data for Huntington's therapy
Published: November 03, 2025 by: Proactive Investors
Sentiment: Negative
Uniqure NV (NASDAQ: QURE) shares plummeted more than 58% in early trading on Monday after the gene therapy company revealed that it was told by the US Food and Drug Administration (FDA) the clinical data for its gene therapy for Huntington's disease is inadequate. Uniqure said the FDA no longer agrees that data from Phase I/II trials, when compared with external control datasets, would be sufficient to support a Biologics License Application (BLA).
Read More
uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – QURE
Published: November 03, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – QURE.
Read More
uniQure: 3-Year Huntington's Data Move AMT-130 From 'Promising' To 'Probable' (Rating Upgrade)
Published: October 28, 2025 by: Seeking Alpha
Sentiment: Positive
uniQure (QURE) is upgraded to Buy following strong 36-month high-dose AMT-130 data for Huntington's disease, showing significant slowing of disease progression. QURE's AMT-130 demonstrated robust clinical benefits, including improved daily activities, cognition, and motor function, despite small sample size and external control limitations. Financially, QURE is well-positioned with over $700 million (pro forma) in cash and ST investments, supporting AMT-130's potential launch and ongoing development.
Read More
uniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Positive
uniQure (QURE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
uniQure: Further Upside Likely As The Opportunity Becomes Better Understood
Published: October 08, 2025 by: Seeking Alpha
Sentiment: Positive
uniQure surged over 300% following strong 3-year data from its Huntington's trial, yet remains undervalued due to skepticism over trial size and the use of external controls. AMT-130's apparent efficacy and prior alignment with the FDA on accelerated approval position AMT-130 for commercialization in the near term. Relatively modest volumes are needed to justify uniQure's current valuation, meaning concerns about demand and the scalability of supply are also likely overstated.
Read More
QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study
Published: September 25, 2025 by: Zacks Investment Research
Sentiment: Positive
uniQure N.V. shares surge nearly 248% after its gene therapy candidate, AMT-130, met key goals in a pivotal Huntington's disease study.
Read More
uniQure N.V. - Special Call
Published: September 24, 2025 by: Seeking Alpha
Sentiment: Neutral
uniQure N.V. - Special Call Company Participants Chiara Russo Matthew Kapusta - CEO & Executive Director Dr. Walid Abi-Saab Kylie O'Keefe - Chief Customer & Strategy Officer Conference Call Participants Sarah Tabrizi Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Debjit Chattopadhyay - Guggenheim Securities, LLC, Research Division Joseph Thome - TD Cowen, Research Division Uy Ear - Mizuho Securities USA LLC, Research Division Kristen Kluska - Cantor Fitzgerald & Co., Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Luca Issi - RBC Capital Markets, Research Division …
Read More
Wall Street Analysts Think uniQure (QURE) Could Surge 142.67%: Read This Before Placing a Bet
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 142.7% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
uniQure N.V. (QURE) Q2 2025 Earnings Call Transcript
Published: July 29, 2025 by: Seeking Alpha
Sentiment: Neutral
uniQure N.V. (NASDAQ:QURE ) Q2 2025 Earnings Call July 29, 2025 8:30 AM ET Company Participants Chiara Russo - Senior Director of Investor Relations Matthew Kapusta - CEO & Executive Director Walid Abi-Saab - Chief Medical Officer Christian Klemt - CFO, Principal Financial Officer & GM of Amsterdam Site Conference Call Participants Debjit Chattopadhyay - Guggenheim Securities, LLC, Research Division Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Joseph Thome - TD Cowen, Research Division Sushila Hernandez - Van Lanschot Kempen Luca Issi - RBC Capital Markets, Research Division Yanan Zhu - Wells Fargo Securities, LLC, Research Division …
Read More
uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Negative
uniQure (QURE) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.89. This compares to a loss of $1.16 per share a year ago.
Read More
uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
~ Alignment with FDA continues to support Accelerated Approval pathway ~ ~ BLA submission planned for first quarter of 2026 ~ ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass.
Read More
3 Top Genomics Stocks to Add to Your Portfolio in 2025
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in the Genomics and Synthetic Biology theme may consider adding these three stocks to their portfolio - Intellia Therapeutics (NTLA), uniQure (QURE) and Verve Therapeutics (VERV).
Read More
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15.
Read More
Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High?
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 161.5% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Negative
UniQure (QURE) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $1.36 per share a year ago.
Read More
uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
~ AMT-130 granted Breakthrough Therapy designation by FDA ~ ~ Initial safety data from third cohort of Phase I/II study show AMT-130 continues to be generally well-tolerated, with no treatment-related serious adverse events ~ ~ Held Type B FDA meetings in the first and second quarters of 2025 to advance BLA preparations for AMT-130; regulatory update expected in the second quarter of 2025 ~ ~ AMT-260 clinical data from first patient to be presented at Epilepsy Therapies & Diagnostics Development Symposium on May 29, 2025 ~ ~ Cash, cash equivalents and current investment securities of approximately $409.0 million as of …
Read More
uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's Data
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Positive
uniQure's lead program for Huntington's Disease is planning to file an application via the accelerated approval pathway. On Monday, May 5th, PTC Therapeutics announced positive results from their phase 2 Huntington's Disease trial. I compare the data from these two treatments and share my thoughts here.
Read More
About uniQure N.V. (QURE)
- IPO Date 2014-02-05
- Website https://www.uniqure.com
- Industry Biotechnology
- CEO Matthew Craig Kapusta
- Employees 209